Drug companies are minting billions on unproven treatments with FDA shortcut


15 May 2023 - Accelerated approvals have helped get promising therapies to market fast — but follow-up research to confirm that the drugs work sometimes falls by the wayside.

When Exondys 51 was approved to treat Duchenne muscular dystrophy, a deadly disease that puts kids in wheelchairs by the time they are teenagers, there was no proof the drug actually slowed the disease. That was seven years ago. The company still hasn’t provided conclusive data to this day.

Read Bloomberg article 

Michael Wonder

Posted by:

Michael Wonder